'Inadvertent Reversal' of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA - TCTMD

'Inadvertent Reversal' of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA  TCTMD

(UPDATED) A serious error in data reporting in the Zilver PTX trial reverses the conclusion that there was a long-term mortality advantage for the ...